Company Overview
Kailera Therapeutics develops next-gen GLP-1 therapies for obesity. Founded 2024 with exclusive global rights (ex-China) from Hengrui Pharmaceuticals. $400M Series A + $600M Series B (Oct 2025, Bain Capital). Lead KAI-9531 (ribupatide): 18% weight loss in Phase 3. Global Phase 3 started Jan 2026. Filed US IPO March 2026. Pipeline includes oral GLP-1 and tri-agonist.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Kailera Therapeutics is an emerging player bringing innovative solutions to the Healthcare Tech market.
Enterprise Scale
With $1000M in revenue, Kailera Therapeutics operates at enterprise scale with proven market validation.
Frequently Asked Questions
Compare Kailera Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Start Comparison →Claim This Profile
Are you from Kailera Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Kailera Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Kailera Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →